Notícias
Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
Novo Nordisk A/S (NYSE:NVO) said its first quarter of 2026 was marked by rapid uptake of its newly launched Wegovy pill in the U.S., continued expansion of its obesity franchise and a series of pipeline and regulatory milestones, even as adjusted sales declined because of lower realized prices. Chi
Novo Nordisk presented new data at the European Congress on Obesity on high dose Wegovy (semaglutide 7.2 mg) from the STEP UP and SELECT trials and a large real world study. The results show substantial and consistent weight loss for women across life stages, including menopause, alongside reductions in body fat. The data highlight additional benefits tied to cardiovascular and mental health, including reduced risks of heart attack, stroke, migraine, and depression in menopausal...
Healthcare stocks advanced late Tuesday afternoon, with the NYSE Healthcare Index and the State Stre
Hims & Hers drops after posting unexpected quarterly loss
Analysts initiated covered Tuesday of IPO stock Kailera Therapeutics, a potential competitor to Lilly and Novo in obesity treatment.
European stock markets fell in late Tuesday trading as oil prices rose after negotiations between th
With its best-in-breed GLP-1 drugs, Eli Lilly is beginning to cement itself as the dominant player in the massive GLP-1 market.
Hims & Hers slashed its profitability outlook for 2026. The news sent Hims stock into free fall Tuesday morning.
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
↗️ Venture Global (VG): The liquefied-natural-gas exporter, which stands to benefit from the closure of the Strait of Hormuz, is due to report results this morning, potentially shedding light on the strength of demand.
By Amina Niasse and Siddhi Mahatole May 11 (Reuters) - Hims & Hers Health missed Wall Street estimates for first-quarter revenue and posted a surprise loss on Monday, as the telehealth company's shift
Cellular Intelligence gains rights to Novo's early-stage Parkinson's program and plans a mid-stage study early next year.
The telehealth platform posted a quarterly loss of $92.1 million, driven by higher expenses, including those tied to operations, technology and general and administrative functions.
Investing.com -- Hims & Hers missed first-quarter earnings estimates, posting a loss as weakness in its American operations offset gains overseas.
Novo Nordisk (CPSE:NOVO B) has licensed its clinical-stage allogeneic cell therapy program for Parkinson's disease to Cellular Intelligence. The program includes an ongoing Phase 1/2 trial and holds FDA Fast Track status. Novo Nordisk is exiting direct cell therapy operations while taking an equity stake in Cellular Intelligence. Cellular Intelligence plans to use its AI platform to support development of the Parkinson's therapy. Novo Nordisk, trading at DKK300.6, is best known for its GLP...
Eli Lilly faces challenges in the GLP-1 market, with Novo Nordisk gaining a timing advantage in both injectable and oral drug approvals.
Cellular Intelligence is acquiring STEM-PD, a Phase 2-ready cell therapy, and plans to use AI to accelerate development and manufacturing
Novo Nordisk shuttered its cell therapy unit in October 2025, with assets now moving to new hands.
Novo Nordisk stock jumps 21% in a month after a Q1 beat and stronger GLP-1 demand, but pricing pressure and Eli Lilly rivalry still cloud its 2026 outlook.
Shares in Novo Nordisk (NYSE:NVO) drew a cautious reception from Citi following first-quarter results that beat consensus expectations, with the bank raising its target price but retaining a neutral rating as concerns over portfolio price erosion and long-term obesity market competition outweigh...
Hims & Hers Health (NYSE:HIMS) has launched Labs AI, an AI care agent that provides users with personalized, clinically vetted interpretations of their lab results. The company is also expanding into FDA-approved GLP-1 weight loss medications through partnerships with major pharmaceutical companies, including Novo Nordisk and Eli Lilly. These moves come as NYSE:HIMS trades at $25.65, with the stock up 31.5% over the past 30 days but down 23.2% year to date and 50.1% over the past year. The...
Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) is one of the best fast growing penny stocks to buy right now. On May 7, Lexicon Pharmaceuticals reported Q1 2026 revenue of $21.1 million, a significant increase from $1.3 million in the prior year, driven by $20.0 million in development milestones from its LX9851 partnership with Novo Nordisk. The company […]
The weight loss drug market is on track to reach almost $100 billion.
Amazon Pharmacy is expanding access to Ozempic pills for type 2 diabetes through same day delivery and kiosk pickups across thousands of US locations. The move broadens digital and retail pharmacy channels for Novo Nordisk, alongside existing access programs with Weight Watchers and GoodRx. This development focuses on oral GLP-1 therapies, adding another distribution layer beyond traditional provider and brick and mortar pharmacy routes. Novo Nordisk (CPSE:NOVO B), trading at DKK290.75, is...
Healthcare stocks declined late Friday afternoon, with the NYSE Healthcare Index and the State Stree
Ozempic and Wegovy demand rose after Novo lowered prices to compete with generics.
The European stock markets were tracking lower, and oil prices were rising Friday following media re